Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)

Lupus Nephritis Clinical Trial

Official title:

A Randomized, Double-Blind, Parallel-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Patients With Lupus Nephritis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03580291
• Other study ID #: 2017001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 1, 2018
• Est. completion date: June 1, 2021

Study information

• Verified date: July 2018
• Source: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Contact: Lingyun Sun, Ph.D M.D.
• Phone: +86(025)83106666
• Email: lingyunsun[@]nju.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lupus nephritis (LN) is one of the most serious complications and the main cause of death in patients with systemic lupus erythematosus (SLE).The investigators have investigated the usefulness, and confirmed the efficacy and safety of mesenchymal stem cells (MSC) treatment of LN in animal models, in vitro experiments and phase I clinical trial. In this study, a randomized, placebo-controlled, parallel group, non-inferiority, prospective, multicenter clinical trial is performed to investigate the efficacy and safety of MSC transplantation in the treatment of LN compared to mycophenolate mofetil (MMF).

Description:

Lupus nephritis (LN) is one of the most serious complications and the main cause of death in patients with systemic lupus erythematosus (SLE). Type III, type IV and type V LN are severe clinical entities with poor prognosis, and its treatment remains challenging. Currently, type III, type IV, type V, type III plus V and type IV plus V LN are treated mainly according to the guidelines developed by KDIGO and the European Association for Anti-Rheumatism and European League Against Rheumatism/European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA). The main therapeutic regimens recommended by these guidelines include glucocorticoid combined with immunosuppressants such as cyclophosphamide (CTX), mycophenolate mofetil (MMF), etc. These medications can significantly induce disease remission and improve the long-term survival. However, some patients do not adequately response to the treatment of the combination of steroids and immunosuppressants, and the disease activity cannot be well-controlled. The high prevalence of steroids and immunosuppressants related adverse effects, such as steroid-related diabetes, bone necrosis, hypertension, peptic ulcer, CTX-related bone marrow and gonadal suppression, MMF-related infection risk and so on, have been found in long-term follow-up study. In addition, to date, there is insufficient data to support the use of new biologics, such as rituximab and abatacept in the induction therapy in patients with LN.

Mesenchymal stem cells (MSCs) can be obtained from several tissues and possess multiple differentiation potencies and immunomodulatory effects. The investigators have investigated the usefulness, and confirmed the efficacy and safety of MSC treatment of LN in animal models, in vitro experiments and phase I clinical trial. The studies also for the first time found that the MSC abnormalities are involved in the onset and development of lupus both in the lupus mice model and in SLE patients. The investigators found that the efficacy of allogeneic (xenogeneic) MSC transplantation is superior to autologous MSC transplantation in LN mice model. Thus, in current opinion, SLE is not only a hematopoietic stem cell disease, but also a mesenchymal stem cell disease. The investigators treated the refractory LN patients with allogenic MSC treatment, the outcomes revealed that the total response rate was 60%, the mortality rate of 2 to 5 years decreased from 35% - 45% to 6%. These results strongly support the use of allogenic MSC transplantation in the refractory LN patients. The mechanisms of MSC treatment include correcting the immune unbalance, inducing immune tolerance, tissue repair and the improvement of organ function. Allogeneic MSC transplantation for the treatment of SLE and other refractory autoimmune diseases have shown significant efficacy and excellent safety. However, these studies have limitations due to the lack of large-scale, multi-center, randomized, controlled, prospective study to further confirm the efficacy of allogeneic MSC transplantation, as well as the guideline for MSC treatment in SLE needs to be developed. Therefore, a randomized, placebo-controlled, parallel group, non-inferiority, prospective, multicenter clinical trial is urgent needed to promote the application of MSC transplantation in SLE treatment, to bring the benefit of the patients with SLE.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 230
• Est. completion date: June 1, 2021
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Subjects who met the American college of Rheumatology (ACR, 1997) classification criteria for SLE;

2. Ages: 18-60 years old (including);

3. Presence of class III, IV, V, III+V or IV+V LN as determined by renal biopsy within 12 weeks of randomization(2003 ISN/RPS LN classification criteria);

4. Morning proteinuria /creatinine ratio >1.0 or 24 hours Proteinuria >1.0g, with or without microscopic hematuria(>5 red blood cells/high-power field);

5. Women of childbearing age agreed to adopt effective contraception measures during the trial period;

6. Urine pregnancy tests were negative in women of childbearing age;

7. Subject signed the informed consent form voluntarily and complied with the requirements of the research program.

Exclusion Criteria:

1. Received MMF, CTX, other potent immunosuppressive agents (including cyclosporine, tacrolimus, Tripterygium wilfordii and leflunomide) or biologics (Rituximab or others) within the past 12 weeks.

2. Previous failure to respond to MMF.

3. Known intolerance to MMF.

4. Renal biopsy showing =50% glomerulus sclerosis.

5. Renal biopsy showing capillary loops necrosis, microthrombus formation in capillary loops, or cellular crescent in =50% of glomeruli.

6. Patients diagnosed with other autoimmune diseases apart from SLE:

dermatomyositis/polymyositis, mixed connective tissue disease, scleroderma, rheumatoid arthritis, etc. However, participants with secondary Sjogren's syndrome are allowed to take part in the study.

7. Patients suffering from severe liver or kidney dysfunction (total bilirubin more than 14mg/L, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal lab value; creatinine clearance rate (Ccr) < 30ml/min or serum creatinine (Scr) =265.2umol/L).

8. Patients with hematological abnormalities (white blood cell <3000/uL, hemoglobin <8g/dL, and/or platelets <50000/uL).

9. Patients diagnosed with severe or uncontrolled cardiovascular, neurological, pulmonary (including obstructive pulmonary disease and interstitial lung disease), hepatic, endocrine (including uncontrolled diabetes mellitus), and gastrointestinal disorders.

10. Known active or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis, atypical mycobacterial infection, granulomatous disease showed by chest X-ray, hepatitis B, hepatitis C, HIV infection and herpes zoster, whereas not including onychomycosis). Any infection requiring hospitalization within 4 weeks prior to enrollment or intravenous antimicrobial treatment within 2 weeks prior to randomization.

11. History of malignancy, including solid tumor and hematologic malignancies (except basal cell carcinoma which has been excised or successfully treated).

12. Women who are pregnant or breastfeeding.

Related Conditions & MeSH terms

• Lupus Nephritis
• Nephritis

Intervention

Other:
• Mesenchymal stem cells
The group receive pulse infusion of MSCs once of 2 x 10^6/kg body weight

Drug:
• Mycophenolate Mofetil
This group receive oral MMF of 2.0 g / d.

Other:
• Placebo of Mesenchymal stem cells
The group receive placebo of Mesenchymal stem cells.

Drug:
• Placebo of Mycophenolate Mofetil
The group receive placebo of oral mycophenolate mofetil.

Locations

Country	Name	City	State
China	The Affiliated Drum Tower Hospital of Nanjing University Medical School	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Lingyun Sun

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total remission rate	Complete remission rate (CR) and partial remission rate (PR)	weeks 24
Secondary	The time for subjects of the two groups to achieve PR and CR		Baseline to weeks 24
Secondary	Levels of 24-hour urinary protein		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Ratio of Urinary Protein / Creatinine		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Levels of serum albumin		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Levels of serum creatinine		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	The estimated glomerular filtration rate ( eGFR )		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Levels of Complement component 3 (C3)		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Levels of Complement component 4 (C4)		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	The antinuclear antibody (ANA) levels		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	The anti-double stranded DNA antibody (dsDNA) levels		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Patient Health Assessment Questionnaire (HAQ) score		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Physician Global Assessment (PhGA) score		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	The (Systemic lupus Erythematosis Disease Activity index) SLEDAI score		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	The (British Isles lupus assessment group ) BILAG score		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	The SLE reaction index		Baseline, weeks 4, 8, 12, 16, 20, 24
Secondary	Total remission rate	Complete remission rate (CR) and partial remission rate (PR)	weeks 12
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0		Baseline to weeks 24